BIOFRONTERA INC
BFRINASDAQ🏆 #4744 by market capEarnings Nov 11US Equity
$0.88▲ $0.06 (+6.64%)
Pre-market · at closeTrack BFRI
Get earnings, price moves & breaking news on Telegram
24h▲ 6.6%
7d▲ 9.9%
14d▲ 3.7%
30d▼ 18.9%
ytd▲ 47.4%
1y▼ 18.9%
🏦Market Cap
$13M
Small Cap
📈Revenue Growth (YoY)
11.8%
Healthy
📊Gross Margin
84.5%
High
💵FCF Margin
-17.2%
Thin
⚖️P/S Ratio
0.3x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.87 – $0.88
- 52-Week Range
- $0.55 – $1.66
- Volume (shares)
- 957
- Avg Volume (shares)
- —
- Shares Outstanding
- 14.9M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $42M
- Last Q Revenue
- $12M
- P/E Ratio
- -1.5
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-0.49
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +111.2%
BIOFRONTERA INC
BFRIFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$42M▲ +11.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.7%▲ +56.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −46.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▲ +29.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.6M▲ +111.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$231K▼ −$752K YoY
StockOtter · stockotter.spaceAbout BIOFRONTERA INC
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.